Clinical Trials Logo

Filter by:
NCT ID: NCT06311981 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

To observe the effect and toxicity of carbon ion radiotherapy on local advanced non-small cell lung cancer over 75 years old patients. Systemic therapy could be targeted therapy, chemotherapy or immunotherapy.

NCT ID: NCT06311968 Recruiting - Radiation Toxicity Clinical Trials

The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

To observe the efficacy and toxicities of post-operative (R0/R1) proton radiotherapy for locally advanced primary thymus epithelial malignancies. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was overall survival and cause-specific survival.

NCT ID: NCT06311955 Recruiting - Clinical trials for Radiotherapy Side Effect

Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.

NCT ID: NCT06311942 Recruiting - HCC Clinical Trials

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. What can be done to improve the surgical prognosis of this group of patients needs to be continuously explored.

NCT ID: NCT06311929 Recruiting - HCC Clinical Trials

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. How to improve the prognosis of this group of patients is an urgent issue to be addressed.

NCT ID: NCT06311890 Recruiting - Acne Clinical Trials

Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the clinical efficacy, safety and tolerability of a photodynamic therapy(PDT) based on a new photosensitizer, Chlorin-e6, in the treatment of moderate to severe acne. The hypothesis is that the therapy has good efficacy, safety and tolerability.

NCT ID: NCT06310954 Recruiting - Clinical trials for Epilepsy in Children

Ketogenic Diet in Pediatric Intractable Epilepsy

Start date: August 11, 2022
Phase: N/A
Study type: Interventional

This study aims to evaluate the efficacy of a ketogenic diet in treating pediatric intractable epilepsy and to explore its relationship with changes in inflammatory markers. The investigators plan to recruit 59 participants with intractable epilepsy, 39 of whom will receive a combination of ketogenic diet and conventional antiepileptic drugs, while 20 will receive only conventional drugs. The study will assess the impact of the ketogenic diet on epilepsy control and inflammatory markers, hoping to discover new treatment strategies.

NCT ID: NCT06310915 Recruiting - Clinical trials for Non-small Cell Lung Cancer Stage IIIB/IV

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

Start date: March 17, 2023
Phase:
Study type: Observational

Oral chemotherapeutic drugs were analyzed in patients with driver gene negative locally advanced/advanced non-small cell lung cancer with PS score 2 A prospective, single-arm, multicenter, observational study on the efficacy and safety of radiochemotherapy combined with PD-1 inhibitor.

NCT ID: NCT06310902 Recruiting - Clinical trials for Pancreatic Neoplasms

Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients

Start date: March 1, 2024
Phase:
Study type: Observational

Preoperative neoadjuvant chemotherapy is widely used in treating patients with borderline resectable pancreatic cancer (BRPC). However, there are limitations in this field. Treatment strategies and definitions for BRPC patients differ, and the efficacy and prognosis of neoadjuvant chemotherapy vary greatly.This study aims to utilize single-cell sequencing technology to investigate in-depth the composition and interactions of the tumor microenvironment in patients from the surgical-only group and the preoperative neoadjuvant chemotherapy group.

NCT ID: NCT06310837 Recruiting - Uveitis Clinical Trials

Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis

Start date: March 27, 2024
Phase: N/A
Study type: Interventional

This is a multi-center, prospective, randomized controlled non-inferior clinical study. A total of 120 subjects with non-infectious intermediate, posterior, or panuveitis were enrolled in Zhongshan Ophthalmic Center and three other centers. They were randomly assigned to the experimental group and the control group according to ( 1 : 1 ). We hypothesized that adalimumab biosimilars combined with immunosuppressive agents in the treatment of non-infectious uveitis is not inferior to glucocorticoids combined with immunosuppressive agents, and there are no additional adverse events and safety issues.